Bio-Tissue, Inc. news
TissueTech, Inc.—a pioneer in the clinical application of cryopreserved human birth tissue products to treat ocular surface disease and disorders, chronic wounds, and musculoskeletal conditions—has unveiled a corporate rebranding, including a name change and a new logo. BioTissue, Inc. and Amniox Medical, Inc. will now both be known under a single commercial, customer facing entity, BioTissue, Inc.
With three decades of continual advancements in regenerative medicine, BioT
TissueTech, Inc., a pioneer in the clinical application of cryopreserved human birth tissue products to treat ocular surface disease and disorders, chronic wounds, and musculoskeletal conditions, has named Ted Davis as the company’s new president and CEO. Davis—a seasoned biologics and orthopedics executive—takes the helm of an emerging company experiencing exponential growth, succeeding TissueTech founder and former CEO Amy Tseng, who retired January 3. Tseng remains a memb
TissueTech, Inc., a pioneer in the clinical application of cryopreserved human birth tissue allografts to treat ocular surface disease and disorders, chronic wounds, and musculoskeletal conditions, announced today that they had completed a new round of hiring for their two commercial subsidiaries Bio-Tissue and Amniox Medical. The recently hired sales representatives and associate sales representatives enrolled in TissueTech’s newly created mentorship program will support organizational
Bio-Tissue, Inc., a TissueTech company and pioneer in the clinical application of human birth tissue allografts to promote regenerative healing for ocular surface disease and disorders, announced today that it has entered into a Vendor Agreement with EyePro Group Purchasing Organization (GPO), LLC. As such, GPO members can now take advantage of membership purchasing volume discounts to access PROKERA® biologic corneal bandages, AmnioGraft® biologic ocular